Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial
IRF5 promotes inflammatory macrophage polarization and TH1-TH17 responses
Global gene expression analysis demonstrated that exogenous IRF5 upregulated or downregulated expression of established phenotypic markers of M1 or M2 macrophages, respectively, suggesting a critical role for IRf5 in M1 macrophage polarization and defining a previously unknown function forIRF5 as a transcriptional repressor.
Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis.
Multiple infusions of cA2 were effective and well tolerated, with the best results occurring at 3 and 10 mg/kg either alone or in combination with MTX in approximately 60% of patients with active RA despite therapy with low-dose MTX.
Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.
- P. Lipsky, D. M. van der Heijde, R. Maini
- MedicineThe New England journal of medicine
- 30 November 2000
In patients with persistently active rheumatoid arthritis despite methotrexate therapy, repeated doses of infliximab in combination with methotRexate provided clinical benefit and halted the progression of joint damage.
An inflammatory cytokine signature predicts COVID-19 severity and survival
It is proposed that serum IL-6 and TNF-α levels should be considered in the management and treatment of patients with COVID-19 to stratify prospective clinical trials, guide resource allocation and inform therapeutic options.
Role of cytokines in rheumatoid arthritis.
Overall these studies demonstrate that analysis of cytokine expression and regulation may yield effective therapeutic targets in inflammatory disease.
Role of interleukin‐1β in postoperative cognitive dysfunction
Whether systemic inflammation, in response to surgical trauma, triggers hippocampal inflammation and subsequent memory impairment, in a mouse model of orthopedic surgery is explored.
Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis
Tumor necrosis factor-α triggers a cytokine cascade yielding postoperative cognitive decline
- N. Terrando, C. Monaco, D. Ma, B. Foxwell, M. Feldmann, M. Maze
- BiologyProceedings of the National Academy of Sciences
- 1 November 2010
Peripheral blockade of TNF-α is able to limit the release of IL-1 and prevent neuroinflammation and cognitive decline in a mouse model of surgery-induced cognitive decline, suggesting a unique therapeutic potential for preemptive treatment with anti-TNF antibody to prevent surgery- induced cognitive decline.
Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned?
Clinical investigations in which the activity of TNF alpha in RA patients was blocked with intravenously administered infliximab, a chimeric anti-TNF alpha monoclonal antibody (mAB), has provided evidence that TNF regulates IL-6, IL-8, MCP-1, and VEGF production, recruitment of immune and inflammatory cells into joints, angiogenesis, and reduction of blood levels of matrix metalloproteinases-1 and -3.